Mesalazine in the induction of clinical and endoscopic remission of mild and moderate ulcerative colitis
https://doi.org/10.21518/2079-701X-2022-16-15-90-97
Abstract
Introduction. Treatment of ulcerative colitis (UC) is necessary to induce remission and subsequently to maintain it. Given the good tolerability, safety and efficacy of mesalazine, it is considered as a first-line therapy for patients with mild to moderate forms.
Aim of the study. To evaluate the effectiveness of induction of clinical and endoscopic remission in patients with mild and moderate UC during 8 weeks therapy with mesalazine in routine clinical practice.
Materials and methods. The study included 40 patients aged 18 to 75 years with mild to moderate attacks of UC who received therapy for 8 weeks. Efficacy was evaluated after 2 and 8 weeks. The dynamics of the quality of life of patients was assessed on the basis of the IBS-QOL questionnaire, satisfaction with therapy was assessed using the Likert scale.
Results. During therapy, the Mayo index significantly decreased, amounting to 4.95 ± 1.74 vs 4.08 ± 1.58 vs 2.53 ± 1.45 for visits 1, 2 and 3, respectively (p < 0.05). The mean value of the level of calprotectin decreased by 2.5 times during 8 weeks of therapy (p < 0.05). After 8 weeks of observation, there were no endoscopic signs of inflammation in 10 patients (25%), in 3 patients (7.5%) endoscopic activity was moderate, and in the remaining 27 subjects (67.5%) it was minimal. The mean IBS-QOL score decreased from 84.25 ± 19.67 to 69.80 ± 17.96 after 8 weeks of therapy (p < 0.05). Satisfaction with treatment according to the Likert scale was 4.13 ± 0.79 points, which corresponds to a high degree of satisfaction. No adverse events were recorded during the entire observation period.
Conclusion. Data analysis demonstrated the effectiveness of induction of clinical and endoscopic remission of mild to moderate forms of left-sided UC and pancolitis with a significant positive effect on the quality of life and good tolerability of the drug.
About the Author
M. V. Shapina
Ryzhikh State Scientific Center of Coloproctology
Russian Federation
Russian Federation
Marina V. Shapina, Cand. Sci. (Med.), Head of the Department of Functional and Inflammatory Bowel Diseases
2, Salyam Adil St., Moscow, 123423
References
1. Gisbert J.P., Chaparro M. Clinical usefulness of proteomics in inflammatory bowel disease: A comprehensive review. J Crohns Colitis. 2019;13(3):374–384. https://doi.org/10.1093/ecco-jcc/jjy158.
2. Jackson B., De Cruz P. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2018;12(11):1079–1100. https://doi.org/10.1080/17474124.2018.1530109.
3. Spiceland C.M., Lodhia N. Endoscopy in inflammatory bowel disease: Role in diagnosis, management, and treatment. World J Gastroenterol. 2018;24(35):4014–4020. https://doi.org/10.3748/wjg.v24.i35.4014.
4. Shah S.C., Itzkowitz S.H. Reappraising risk factors for inflammatory bowel disease-associated neoplasia: implications for colonoscopic surveillance in IBD. J Crohns Colitis. 2020;14(8):1172–1177. https://doi.org/10.1093/ecco-jcc/jjaa040.
5. Khalif I.L., Shapina M.V. Inflammatory bowel disease treatment in Eastern Europe: current status, challenges and needs. Curr Opin Gastroenterol. 2017;33(4):230–233. https://doi.org/10.1097/MOG.0000000000000370.
6. Danese S., Banerjee R., Cummings J.F., Dotan I., Kotze P.G., Leong R.W.L. et al. Consensus recommendations for patient-centered therapy in mildto-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. Intest Res. 2018;16(4):522–528. https://doi.org/10.5217/ir.2018.00073.
7. Pai R.K., Jairath V., Vande Casteele N., Rieder F., Parker C.E., Lauwers G.Y. The emerging role of histologic disease activity assessment in ulcerative colitis. Gastrointest Endosc. 2018;88(6):887–898. https://doi.org/10.1016/j.gie.2018.08.018.
8. Ashton J.J., Ennis S., Beattie R.M. Early-onset paediatric inflammatory bowel disease. Lancet Child Adolesc Health. 2017;1(2):147–158. https://doi.org/10.1016/S2352-4642(17)30017-2.
9. Liu C.Y., Polk D.B. Microbiomes through the Looking Glass: What Do UC? Cell Host Microbe. 2018;24(4):472–474. https://doi.org/10.1016/j.chom.2018.09.013.
10. Terry R., Chintanaboina J., Patel D., Lippert B., Haner M., Price K. et al. Expression of WIF-1 in inflammatory bowel disease. Histol Histopathol. 2019;34(2):149–157. https://doi.org/10.14670/HH-18-031.
11. Yamamoto-Furusho J.K., Fonseca-Camarillo G., Furuzawa-Carballeda J., Sarmiento-Aguilar A., Barreto-Zuñiga R., Martínez-Benitez B., LaraVelazquez M.A. Caspase recruitment domain (CARD) family (CARD9, CARD10, CARD11, CARD14 and CARD15) are increased during active inflammation in patients with inflammatory bowel disease. J Inflamm (Lond). 2018;15:13. https://doi.org/10.1186/s12950-018-0189-4.
12. Lynch W.D., Hsu R. Ulcerative Colitis. Treasure Island (FL): StatPearls Publishing; 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK459282/.
13. Peyrin-Biroulet L., Sandborn W., Sands B.E., Reinisch W., Bemelman W., Bryant R.V. et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am. J Gastroenterol. 2015;110(9):1324–1238. https://doi.org/10.1038/ajg.2015.233.
14. Le Berre C., Peyrin-Biroulet L. Selecting Endpoints for DiseaseModification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD. Gastroenterology. 2021:60(5):1452–1460.e21. https://doi.org/10.1053/j.gastro.2020.10.065.
15. Mouzas I.A., Pallis A.G. Assessing quality of life in medical trials on patients with inflammatory bowel disease. Ann Gastroenterol. 2000;13(4):261–263. Available at: http://www.annalsgastro.gr/index.php/annalsgastro/article/view/33.
16. Ивашкин В.Т., Шелыгин Ю.А., Белоусова Е.А., Абдулганиева Д.И., Алексеева О.А., Ачкасов С.И. и др. Проект клинических рекомендаций по диагностике и лечению язвенного колита. Колопроктология. 2019;18(4):7–36. Режим доступа: https://www.ruproctology.com/jour/article/view/1541. Ivashkin V.T., Shelygin Yu.A., Belousova E.A., Abdulganieva D.I., Alekseeva O.A., Achkasov S.I. et al. Project: clinical guidelines for the diagnostics and treatment of ulcerative colitis. Koloproktologia. 2019;18(4):7–36. (In Russ.) Available at: https://www.ruproctology.com/jour/article/view/1541.
17. Rubin D.T., Ananthakrishnan A.N., Siegel C.A., Sauer B.G., Long M.D. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384–413. https://doi.org/10.14309/ajg.0000000000000152.
18. Dignass A., Lindsay J.O., Sturm A., Windsor A., Colombel J.F., Allez M. et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6(10):991–1030. https://doi.org/10.1016/j.crohns.2012.09.002.
19. Lamb C.A., Kennedy N.A., Raine T., Hendy P.A., Smith P.J., Limdi J.K. et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl. 3):s1–s106. https://doi.org/10.1136/gutjnl-2019-318484.
20. Тарасова Д.Д., Шилова Л.Н., Королева М.В. Современные аспекты терапии язвенного колита. Лекарственный вестник. 2019;13(2):28–32. Режим доступа: https://www.volgmed.ru/uploads/journals/articles/1567508603-drugs-bulletin-2019-2-3400.pdf. Tarasova D.D., Shilova L.N., Koroleva M.V. Modern aspects of the treatment of ulcerative colitis. Lekarstvennyi Vestnik. 2019;13(2):28–32. (In Russ.) Available at: https://www.volgmed.ru/uploads/journals/articles/1567508603-drugs-bulletin-2019-2-3400.pdf.
21. Wang Y., Parker C.E., Feagan B.G., MacDonald J.K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;2016(5):CD000544. https://doi.org/10.1002/14651858.CD000544.pub4.
22. Murray A., Nguyen T.M., Parker C.E., Feagan B.G., MacDonald J.K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.Cochrane Database Syst Rev. 2020;8(8):CD000543. https://doi.org/10.1002/14651858.CD000543.pub5.
23. Абдулхаков С.Р., Абдулхаков Р.А. Неспецифичeский язвенный колит: современные подходы к диагностике и лечению. Вестник современной клинической медицины. 2009;2(1):32–41. Режим доступа: http://vskmjournal.org/images/Files/Issues_Archive/2009/Issue_1/VSKM_2009_N_1.pdf. Abdulkhakov S.R., Abdulkhakov R.A. Non-specific ulcerative colitis: up-to-date approaches to diagnostics and treatment. Vestnik Sovremennoi Klinicheskoi Mediciny. 2009;2(1):32–41. (In Russ.) Available at: http://vskmjournal.org/images/Files/Issues_Archive/2009/Issue_1/VSKM_2009_N_1.pdf.
24. Ситкин С.И. Месалазин в терапии воспалительных заболеваний кишечника. Фармакокинетика и клиническая эффективность. Гастроэнтерология Санкт-Петербурга. 2002;(1):15. Sitkin S.I. Mesalazine in the treatment of inflammatory bowel disease. Pharmacokinetics and clinical efficacy. Gastroenterology of St Petersburg. 2002;(1):15. (In Russ.)
25. Dew M.J., Harries A.D., Evans N., Evans B.K., Rhodes J. Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. Br Med J (Clin Res Ed). 1983;287(6384):23–24. https://doi.org/10.1136/bmj.287.6384.23.
Review
For citations:
Shapina MV. Mesalazine in the induction of clinical and endoscopic remission of mild and moderate ulcerative colitis. Meditsinskiy sovet = Medical Council. 2022;(15):90-97. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-15-90-97
Views:
315
Email this article 